PromiCell, Inc. presents during JP Morgan's 2026 Healthcare Conference
-
French court confirms Moroccan football star Hakimi will stand trial for rape
-
South Korean leader says told Trump sanctions on North are 'ineffective'
-
Deadly Philippines quake turns seabed into shore
-
Stocks rally falters, oil rises as US-Iran talks postponed
-
S. Korean leader says he told Trump sanctions on North are 'ineffective'
-
Indonesia to capture last-known wild Bornean rhino for IVF
-
No vaccine, conflict, mistrust: Ebola's return to DR Congo
-
USA, Australia eye World Cup knockout rounds, Brazil in action
-
AI museum brings sights, sounds and smells of the rainforest
-
Iran to lodge complaint with FIFA over World Cup restrictions
-
'Old dog' Slipper out of retirement for Wallabies' Nations Championship campaign
-
New Zealand minister defends fishers after two orcas killed in net
-
Mexico into World Cup last 32, Canada celebrate historic win
-
Seoul record leads most Asian markets higher, crude extends losses
-
Co-hosts Mexico first team into World Cup knockout rounds
-
Burnham wins key UK poll, paving way for bid to challenge PM Starmer
-
Erasmus under 'no illusions' as tough Springboks season kicks off
-
'Pico' Lopes -- Cape Verde defender's journey from Ireland to World Cup
-
100 Colombian guerrillas disarm in deal with leftist government
-
'Pretty special': captains eye Super Rugby glory in clash of top seeds
-
Football 'ambassador' and fan favorite: a duck becomes a star in Mexico
-
Ivory Coast's Diomande living World Cup dream, dealing with tragedy
-
Slipper out of retirement for Wallabies' Nations Championship campaign
-
Australia seek 'respect' from US amid World Cup 'layup' row
-
New Zealand's Payne joins Paraguayan powerhouse after Instagram fame
-
Japan doctor-turned-author moots amputations to ease care crunch
-
Clark seizes four-stroke lead at darkness-halted US Open
-
Fossils challenge assumptions on how animals adapted to land
-
From private enterprise to property: Cuba's reforms unpacked
-
Canada romp to first World Cup win, Switzerland thump Bosnia
-
'Last ride': US says goodbye to Air Force One as Qatari jet awaits
-
Venezuela govt, opposition hold US-backed talks on democratic transition
-
Gabriel tells Brazil to turn the page against Haiti at World Cup
-
Horror injury overshadows Canada's first World Cup win
-
Cuba adopts historic package of free-market reforms
-
Swiss wunderkind Manzambi scores 'childhood dream' brace
-
US faces tough path to new Iran nuclear deal
-
Good US Open shots not good enough for 2-over Scheffler
-
Cuba unveils historic package of free-market reforms
-
Subs send Swiss to World Cup rout of Bosnia-Herzegovina
-
Stokes set for England return in New Zealand finale - reports
-
McIlroy pleased with reduced green speeds in US Open winds
-
Quarantine over for almost all hantavirus ship passengers, crew
-
US stocks resume upward climb as dollar advances again after Fed outlook
-
Ex-presidents and stars, but no Trump, turn out for Obama Library
-
Stevens seizes US Open lead with McIlroy, Aberg one back
-
Al-Qaeda-linked jihadists attack Niger airport, 11 soldiers killed
-
'Big-game' Bellingham shows his worth for England at World Cup
-
New Zealand's Henry rocks England in 2nd Test after Phillips century
-
Vance warns Israel against criticizing US-Iran deal
PromiCell, Inc. presents during JP Morgan's 2026 Healthcare Conference
MIAMI, FL / ACCESS Newswire / January 9, 2026 / PromiCell, Inc. (the "Company"), a clinical-stage cellular immunotherapy company uniquely positioned to advance potentially curative cell therapies for cancer patients, today announced that the Company's Chief Medical Officer, John Lee, MD, Ph.D., will present interim results of the Company's lead asset PRO CAR - 201A, a STEAP1 directed CAR T cell that is currently in the clinic as a first-in-human phase 1 trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC), at Biotech Showcase 2026 in San Francisco, California on Monday, January 12, 2025 at 11:15 am PST at the Franciscan D (Ballroom Level).
About PromiCell, Inc.
PromiCell, is a clinical-stage cellular immunotherapy company with product candidates representing highly differentiated and novel CAR T and TCR T platforms to be developed across separate solid and hematologic types of cancer. Our pipeline of innovative products includes STEAP 1 CAR T cells, HA-1 TCR T cells and CD 33 CAR T cells, applicable for the treatment of patients with mCRPC, Ewing Sarcoma, recurrent leukemia and acute myeloid leukemia. Our next-generation chimeric antigen receptor CAR T cell therapies are designed to address key mechanisms of tumor escape, disease relapse, and immune evasion. Our scientists are pioneers in CAR T-cell therapy, united in a mission to outsmart cancer and deliver more cures for patients. Learn more at www.promicell.com.
Contact:
305-433-1287
[email protected]
SOURCE: Promicell
View the original press release on ACCESS Newswire
H.Seidel--BTB
